Valuation: Apogee Therapeutics, Inc.

Market Cap 10.08B 8.73B 8.14B 7.48B 14.13B 958B 14.29B 95.61B 37.53B 479B 37.85B 37.02B 1,588B P/E 2026 *
-31.1x
P/E 2027 * -24x
Enterprise Value 9.1B 7.88B 7.35B 6.76B 12.75B 865B 12.9B 86.32B 33.88B 433B 34.17B 33.42B 1,434B EV / Sales 2026 *
1,001x
EV / Sales 2027 * 747x
Free-Float
94.51%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.03%
1 week+0.02%
Current month+0.10%
1 month+0.99%
3 months+61.16%
6 months+116.05%
Current year+77.84%
1 week 134.03
Extreme 134.03
134.35
1 month 133.18
Extreme 133.18
134.46
Current year 60.35
Extreme 60.35
134.46
1 year 34.34
Extreme 34.34
134.46
3 years 14.19
Extreme 14.19
134.46
5 years 14.19
Extreme 14.19
134.46
10 years 14.19
Extreme 14.19
134.46
Manager TitleAgeSince
Chief Executive Officer 36 31/08/2022
Director of Finance/CFO 60 31/12/2022
Chief Tech/Sci/R&D Officer - 30/04/2023
Director TitleAgeSince
Director/Board Member 54 21/06/2023
Director/Board Member 62 31/05/2023
Director/Board Member 36 31/05/2023
Date Insider Type Main position Quantity % Market Cap.
24/07/26 Don

Chief Financial Officer

-15,000 0.0268%
14/07/26 Don

Chief Technology Officer

-8,000 0.0143%
10/07/26 Don

Chief Executive Officer

-75,046 0.1340%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+0.02%+250.20%+548.45% 10.08B
+0.86%-0.84%+3.67%+15.34% 48.57B
+1.98%+9.05%+413.94%+532.17% 41.95B
+3.44%-4.65%+28.34%+8.81% 38.85B
+1.40%+0.10%+6.61%+61.93% 37.24B
+2.42%+5.72%+12.38%+44.79% 30.67B
-0.16%-3.11% - - 16.1B
+2.20%+0.48%+34.71%+127.15% 16.41B
+0.26%+1.84%+8.14%+18.97% 13.97B
+4.25%-8.23%-1.49%-35.46% 12.62B
Average +1.67%-0.70%+84.05%+146.91% 26.64B
Weighted average by Cap. +1.79%-0.11%+89.69%+137.89%

Financials

2026 *2027 *
Net sales 9.09M 7.87M 7.34M 6.75M 12.74M 864M 12.89M 86.25M 33.85M 433M 34.14M 33.39M 1.43B 12.5M 10.83M 10.09M 9.28M 17.52M 1.19B 17.72M 119M 46.55M 595M 46.95M 45.91M 1.97B
Net income -318M -275M -256M -236M -445M -30.19B -450M -3.01B -1.18B -15.11B -1.19B -1.17B -50.03B -416M -361M -336M -309M -584M -39.6B -590M -3.95B -1.55B -19.81B -1.56B -1.53B -65.62B
Net Debt -980M -848M -791M -727M -1.37B -93.14B -1.39B -9.29B -3.65B -46.6B -3.68B -3.6B -154B -740M -641M -598M -550M -1.04B -70.39B -1.05B -7.02B -2.76B -35.22B -2.78B -2.72B -117B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
05/08/26 US$134.23 +0.03% 1,961,062
04/08/26 US$134.19 +0.06% 2,377,913
03/08/26 US$134.11 +0.01% 1,059,851
31/07/26 US$134.09 -0.16% 1,744,242
30/07/26 US$134.30 +0.07% 840,599
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
134.23USD
Average target price
130.53USD
Spread / Average Target
-2.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock